LONDON, GREATER LONDON, UNITED KINGDOM, March 4, 2025 /EINPresswire / -- How Has the Beyfortus Market Expanded in Recent Years? The Beyfortus market has experienced significant growth, driven by ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

The panel voted 21 to zero that Beyfortus (nirsevimab) appears to be safe and effective at preventing RSV infections in newborns and infants as they face their first RSV season, setting the drug ...

Upcoming market catalysts for the second quarter of 2025 include the US approval decisions for clesrovimab (MK-1654) for respiratory syncytial virus (RSV) prophylaxis, sebetralstat for hereditary ...

Getting vaccinated during pregnancy protects your newborn from severe infection during the first critical months of life.

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Dupixent made about €13 billion in its first full year, while Beyfortus, a novel RSV vaccination for babies, became a bestseller with €1.7 billion. SNY’s EPS grew 4.1% at CER to €7.12 ...

A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

vaccine for pregnant individuals and the monoclonal antibody nirsevimab (Beyfortus) for newborns—has shown high uptake in a recent cohort study. 1 Conducted at a single academic center ...

Beyfortus is the RSV vaccine for children. These doses are allocated to doctor's offices and hospitals through the CDC’s Vaccines for Children Program and commercial channels. Residents in Bucks ...